Last week, sponsors of neglected tropical disease drug applications got a glimpse into the minds of the U.S. Food and Drug Administration, which released guidance about how it plans to handle new drug applications for diseases such as malaria, dengue, cholera, and 11 other parasitic and bacterial infectious diseases that disproportionately affect developing nations.